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Abstract
Metabolic changes induced by oncogenic drivers of cancer contribute to tumor growth and are 
attractive targets for cancer treatment. Here, we found that increased growth of PTEN mutant cells 
was dependent on glutamine flux through the de novo pyrimidine synthesis pathway, which 
created sensitivity to inhibition of dihydroorotate dehydrogenase, a rate limiting enzyme for 
pyrimidine ring synthesis. S-phase PTEN mutant cells showed increased numbers of replication 
forks, and inhibitors of dihydroorotate dehydrogenase led to chromosome breaks and cell death 
due to inadequate ATR activation and DNA damage at replication forks. Our findings indicate that 
enhanced glutamine flux generates vulnerability to dihydroorotate dehydrogenase inhibition, 
which then causes synthetic lethality in PTEN deficient cells due to inherent defects in ATR 
activation. Inhibition of dihydroorotate dehydrogenase could thus be a promising therapy for 
patients with PTEN mutant cancers.
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The Warburg effect, describing heightened aerobic glycolysis in tumors, played a key role in 
launching the field of cancer metabolism. Subsequent studies have found that glutamine is 
also vital for growth by fueling tricarboxylic acid cycle intermediates, phospholipid and 
nucleotide synthesis, and NADPH (1). Oncogenic signaling pathways have been shown to 
play a major role in reprogramming glucose and glutamine metabolism, thus connecting 
genetic mutations with metabolic alterations (2–5). PTEN (phosphatase and tensin homolog 
deleted on chromosome 10) is one of the most commonly mutated tumor suppressors and is 
a fulcrum of multiple cellular functions (6,7). PTEN’s canonical role is as a lipid 
phosphatase for phosphatidylinositol-3,4,5-trisphosphate, central to the phosphoinositide-3 
kinase (PI3K) pathway, limiting AKT, mTOR, and RAC signaling (8–11). Inactivation of 
PTEN enhances glucose metabolism and diminishes DNA repair and DNA damage 
checkpoint pathways (12–14). Furthermore, deficient homologous recombination in PTEN 
mutant cells leads to sensitivity to gamma-irradiation and PARP inhibitors (13,15). The role 
of PTEN in metabolism, however, is incompletely understood, and in this study we examine 
the metabolic consequences of PTEN loss and the resulting vulnerability of PTEN mutant 
tumors.
Results
To better understand the relationship between PTEN, cell growth, and cellular metabolism, 
we generated Pten flox/flox primary mouse embryonic fibroblasts. Pten−/− MEFs 
proliferated at a higher rate than WT MEFs but showed no difference in cell death (Fig. 1A; 
Supplementary Fig. S1, A–C). This increased proliferation was associated with an increase 
in the proportion of cells within S-phase and higher numbers of replication forks per S-phase 
cell (Fig. 1, B–D; Supplementary Fig. S1D). There was no difference in mitochondrial 
function between Pten−/− and WT MEFs, suggesting a different source of altered replication 
(Supplementary Fig. S1, E–F).
Upon testing the potential role of glutamine for explaining the increased growth of Pten−/− 
cells, we found that the growth advantage of Pten−/− MEFs was dependent on glutamine: 
depletion of glutamine or addition of the glutaminase inhibitor CB-839 collapsed the growth 
difference between Pten−/− and WT MEFs (Fig. 1, E–F). To better understand the 
relationship between PTEN and glutamine, we performed steady state metabolomic profiling 
of 292 aqueous metabolites to determine if loss of PTEN triggers abnormal cellular 
metabolism to increase growth. Unbiased global metabolic assessment of WT and Pten−/− 
MEFs revealed that seven of the ten most upregulated pathways in Pten−/− MEFs involved 
nucleotide synthesis and DNA metabolism, including a higher concentration of pyrimidine 
2-deoxyribonucleotides in Pten−/− MEFs (Fig. 1G; Supplementary Fig. S2, A–B). Because 
glutamine contributes both nitrogen and carbon to pyrimidines (16), we performed metabolic 
flux analysis with heavy-isotope 15N or 13C-labeled glutamine, which showed increased 
synthesis of dihydroorotate, orotate, and other components of the de novo pyrimidine 
synthesis pathway in Pten−/− MEFs relative to WT (Fig. 1, H–I; Supplementary Fig. S2C). 
In addition, the pyrimidine metabolism gene set was upregulated in mRNA from Pten−/− 
MEFs (Supplementary Fig. S2D). Although Pten−/− fibroblasts had somewhat elevated 
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stead-state glucose metabolism and glycolytic flux relative to WT, depletion of glucose from 
the medium did not rescue the differences in cell growth, suggesting that glutamine was 
more critical for the growth advantage of Pten−/− cells (Supplementary Fig. S2, A, E–F). 
Nucleotide synthesis is a prerequisite for cellular growth, and Pten−/− MEFs appear to 
channel glutamine for this purpose.
The fourth step of de novo pyrimidine synthesis in mammals is the conversion of 
dihydroorotate to orotate, catalyzed by dihydroorotate dehydrogenase (DHODH) (17). To 
see if orotate contributes to the growth effects observed, the effect of DHODH inhibitors on 
cell proliferation was examined. Pten−/− MEFs were about 3-fold more sensitive to 
leflunomide, a DHODH inhibitor, (18) than WT MEFs were (Fig. 2A; Supplementary Fig. 
S3, A–B). Pten−/− MEFs were also more sensitive to A771726, the active metabolite of 
leflunomide (18,19), as well as another DHODH inhibitor, brequinar (18), indicating that the 
observed effects were likely through DHODH (Fig. 2A).
To determine whether PTEN genotype is predictive of sensitivity to DHODH inhibition in 
cancer cells, we tested human breast, glioblastoma, and prostate cell lines with DHODH 
inhibitors. Consistently, the GI50 of the PTEN mutant lines was lower than that of WT (Fig. 
2B; Supplementary Fig. S3C). Mouse cancer lines MCCL-357 (Myc, Pten−/−) and CaP8 
(Pten−/−) were also more sensitive than mouse cancer lines MCCL-278 (Myc, Pik3ca 
H1047R) and Myc-CaP (Myc) were (Fig. 2C; Supplementary Fig. S3, D–E) (20,21). 
Moreover, Pten−/− MEFs, PTEN mutant human breast cancer cell lines, and Pten−/− mouse 
breast lines displayed an increased accumulation of dead cells over time upon treatment with 
leflunomide (Fig. 2, D–E; Supplementary Fig. S3F). It is important to note that sensitivity to 
leflunomide was not associated with the proliferation rates of human breast, mouse breast, or 
mouse prostate tumor cell lines (Fig. 2F; Supplementary Fig. S3, G-H). Additionally, 
consistent with previous reports (22), we found that Pten homozygous deletion caused 
greater AKT phosphorylation than Pik3ca missense mutation did. This was particularly 
prominent in the nuclear fractions, where AKT may phosphorylate nuclear substrates (Fig 
2G; Supplementary Fig. S3, I–J).
To independently test if DHODH inhibition is detrimental to PTEN deficient cells, we 
performed a rescue experiment with orotate, the metabolite directly downstream of 
DHODH, as well as with uridine. Increasing concentrations of orotate or uridine rescued 
growth inhibition by leflunomide (Fig. 2, H-K; Supplementary Fig. S4, A–C). In addition, 
siRNA against DHODH preferentially killed PTEN mutant cells, verifying that DHODH 
was the target of the small molecule inhibitors (Supplementary Fig. S4D). There was no 
endogenous difference in DHODH protein level between Pten−/− and WT MEFs, and 
A771726 did not affect PI3K signaling (Supplementary Fig. S4, E–F). Consistent with prior 
reports, CAD phosphorylation downstream of mTORC1 was increased in Pten−/− cells, 
likely contributing to the push of glutamine flux into the pyrimidine synthesis pathway 
(Supplementary Fig. S4, G–H) (5). Pten−/− cells were more sensitive than WT cells to the 
mTOR inhibitor RAD001 as expected, but RAD001 did not synergize with leflunomide 
(Supplementary Fig. S4, I–K) (10,23). Interestingly, treatment with nucleotide analog 
inhibitors – 5-flurouracil or mercaptopurine – did not show a differential sensitivity, 
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demonstrating that Pten−/− MEFs are selectively vulnerable to inhibition of de novo 
pyrimidine synthesis (Supplementary Fig. S4, L–M).
Myc activation is known to cause glutamine addiction (4). CaP8 (Pten−/−) cells were nearly 
as sensitive to glutamine deprivation as Myc-CaP (Myc oncogene transformed) cells were, 
substantiating that a notable level of glutamine dependency is also elicited by PTEN loss 
(Supplementary Fig. S4N). Since Myc-CaP cells were resistant to leflunomide, it seems it is 
not the entry alone of glutamine but its flux into pyrimidines that is important 
(Supplementary Fig. S3D). While MYC is known to largely direct glutamine to the TCA 
cycle and phospholipid synthesis (4), our data suggest that Pten loss in MEFs causes 
glutamine to cascade through the de novo pyrimidine synthesis pathway, creating the point 
of vulnerability to DHODH inhibition.
To determine how clinically relevant leflunomide may be as a targeted cancer therapy, we 
grew patient-derived glioblastomas as 3-dimensional neurospheres. Re-formation of 
neurospheres was inhibited at lower concentrations of leflunomide in PTEN deficient 
samples (Fig. 3A; Supplementary Fig. S5A). Additionally, we treated two PTEN mutant 
triple negative breast cancer xenografts with leflunomide, dosing orally as is done clinically. 
Tumors slowed or regressed upon treatment; remarkably, even very large tumors (4×107 
photons) regressed after only 1 week of treatment, indicating that leflunomide may have use 
for neoadjuvant therapy (Fig. 3, B–C; Supplementary Fig. S5B). To ensure the effect in vivo 
is specific to PTEN loss, MCCL-357 and MCCL-278 xenografts were treated with 
leflunomide; MCCL-357 xenografts had a 4-fold better response than MCCL-278 xenografts 
did (Supplementary Fig. S5C).
It is logical that a blockade of pyrimidine synthesis would stop cells from dividing, and 
leflunomide has been previously established as a cytostatic drug (18). What is more 
enigmatic, however, is why it would cause PTEN−/− cells to die. Consistent with prior 
reports (24), Pten−/− MEFs had a higher level of gamma-H2AX, an indicator of DNA 
damage (Fig. 4A). We hypothesized that the dearth of pyrimidine deoxynucleotides caused 
by DHODH inhibition would exacerbate this defect, and discovered that leflunomide (or 
A771726) augmented DNA damage to a significantly greater degree in PTEN deficient cells 
and that this damage co-localized with replication forks labeled with EdU (Fig. 4, B–D; 
Supplementary Fig. S6, A–B). Leflunomide-induced DNA damage was rescued by uridine, 
demonstrating that damage is likely instigated by pyrimidine depletion (Fig. 4E). The greater 
number of replication forks we described in Pten−/− MEFs remained intact after 24h of 
treatment with leflunomide, showing that the cells continue to replicate despite the presence 
of DNA damage (Fig. 1B, 4F; Supplementary Fig. S6, C–D).
Depletion of nucleotide pools normally activates the ATR checkpoint at replication forks in 
S-phase cells (25). ATR checkpoint activation at stalled forks requires two signals, one 
through single-strand DNA binding protein (RPA) interaction with single-strand DNA to 
recruit the ATRIP-ATR complex, and a second signal through TOPBP1 interaction with the 
ATR activation domain (26,27). Deletion of PTEN in cells is known cause poor ATR 
checkpoint activation, and AKT phosphorylation of TOPBP1 on serine 1159 and CHK1 on 
serine 280 inhibits their function (14,24,28,29). Prior work showed increased CHK1 serine 
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280 phosphorylation in PTEN−/− cells, which reduced CHK1 activity (24). We found greater 
TOPBP1 S1159 phosphorylation and concomitantly less TOPBP1 localization to replication 
forks in Pten−/− cells (Fig. 4G; Supplementary Fig. S6, E–F). Diminished AKT activity 
through PI3K inhibition also reduced leflunomide-induced DNA damage (Supplementary 
Fig. S6G). To further investigate the response to DNA damage occurring at Pten−/− forks, we 
examined the interaction of RPA and gamma-H2AX by flow cytometry. An increase in RPA 
signal was first achieved regardless of PTEN genotype in the presence of A771726, followed 
by a shift toward both RPA and gamma-H2AX-positive cells in Pten−/− MCCL-357 but not 
in Pten WT MCCL-278 cells (Fig. 4H). Moreover, gamma-H2AX appeared almost 
exclusively in RPA-positive MCCL-357 cells treated with A771726 (Supplementary Fig. 
S6H). A771726 also triggered ATR phosphorylation of CHK1 at serine 345 in Pten WT but 
to a much lesser extent in Pten−/− cells (Fig. 4I; Supplementary Fig. S6I). Thus, Pten−/− cells 
appear to be incapable of generating an appropriate activation of the ATR-CHK1 checkpoint 
at replication forks. Activation of CHK1 in MCCL-278 cells declined as RPA declined, 
suggesting that Pten WT cells eventually recovered from DHODH inhibition, while Pten−/− 
cells instead accumulated damage at 18h (Fig. 4I). By 48h this genomic stress manifested in 
a greater number of chromosome gaps, breaks, and multiradial formations in MCCL-357 
cells treated with A771726 compared to MCCL-278 cells (Fig. 4, J–K; Supplementary Fig. 
S6, J–K). These findings are consistent with the sensitivity to hydroxyurea that occurs in the 
setting of an ATR inhibitor (30). Furthermore, we were able to rescue DNA damage and cell 
death in leflunomide-treated PTEN mutant cells by transfecting cells with TOPBP1 and 
CHK1 mutants incapable of being phosphorylated by AKT (S1159A and S280A, 
respectively), demonstrating that the synthetic lethality between pyrimidine depletion and 
mutation of PTEN is due to the AKT-mediated defects in the ATR pathway (Fig. 4, L–M).
Based on our data, we propose that inhibition of DHODH in PTEN deficient cells first 
causes stalled forks due to inadequate nucleotide pools required to support replication, and 
that sustained treatment leads to insufficient ATR activation due to AKT phosphorylation of 
TOPBP1 and CHK1, leading to a buildup of DNA damage and cell death. PTEN WT cells 
do not exhibit this dependency on pyrimidine synthesis and have fewer forks per cell, 
perhaps because ATR-CHK1 coordinates origin firing during S-phase (31). In PTEN WT 
cells, treatment initially increased the RPA signal and triggered transient phosphorylation of 
CHK1, while longer treatment led to abated RPA with little concurrent increase in gamma-
H2AX, explaining the largely unaffected WT population upon DHODH inhibition 
(Supplementary Fig. S7). While Pik3ca mutant cells also exhibit AKT signaling, their 
relative resistance to DHODH inhibitors suggests that a PI3K signaling dosage-effect due to 
their lower level of AKT activation may be important.
Discussion
PTEN loss leads to chemoresistance in prostate cancer, a poorer response to trastuzumab in 
triple negative breast cancer, and a shorter survival time in patients with gliomas (32). 
Targeting consequences of PTEN loss could be beneficial, particularly since the standard of 
care for the aforementioned cancers is primarily chemotherapy and radiation. Inhibiting 
DHODH has the advantage of affecting a specific pathway of glutamine flux downstream of 
glutaminase, thus preserving glutamine’s other important functions in the cell. This 
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increases the specificity of DHODH inhibitors to cells which are dependent on glutamine’s 
role in pyrimidine synthesis per se, and is perhaps why their toxicity is low enough to be 
taken as a daily medication by rheumatoid arthritis and multiple sclerosis patients (19). It 
has been shown that leflunomide inhibits B-cell and T-cell proliferation, contributing to its 
immunomodulating effects (33,34). It is possible that preexisting B and T cells can still 
function in the presence of DHODH inhibitors, thus potentially arguing for the benefit of 
immunotherapy in combination with a DHODH inhibitor, perhaps in a metronomic therapy 
pattern. Here, we show that high activation of AKT toward TOPBP1 and CHK1 that down 
regulates ATR activation at replication forks compounded with enhanced pyrimidine flux 
that both occur as a consequence of PTEN inactivation contributes to the observed synthetic 
lethality between PTEN mutation and DHODH inhibition. We hope that DHODH inhibitors 
will be a promising therapy for patients with PTEN deficient cancers.
Methods
Immunoblotting
Samples were lysed in 2x Laemelli sample buffer before separation by SDS-PAGE and 
transferring to PVDF membranes, blocked with 10% milk in TBST for 1 hour, and 
incubated with primary antibodies overnight. Antibodies: PTEN 6H2.1 (Millipore 04-035), 
DHODH (Protein Tech 14877-1-AP), vinculin (Sigma), pCHK1 (Cell Signaling 2341), 
CHK1 G-4 (Santa Cruz sc-8408), pCAD (Cell Signaling 12662), CAD (Cell Signaling 
11933). HRP conjugated secondary antibodies were used to detect protein signals.
Cell culture
MEFs and mouse breast tumor lines: DMEM (Corning mt10013cv) supplemented with 10% 
FBS (Atlanta Biologicals), 1% pen/strep (Fisher 30002ci) and 2mM L-glutamine (total 
6mM) (Fisher MT25005CI). MDA-MB468, MDA-MB 231, Myc-CaP (2015), and U87: 
DMEM supplemented with 10% FBS and 1% pen/strep. HCC1419, HCC1187, HCC 1937, 
HCC 1806, BT549, ZR75-1, PC3, LNCAP, DBTRG: RPMI (Fisher 10040cv) supplemented 
with 10% FBS and 1% pen/strep. CaP8 cells (2015): DMEM with 10% FBS, 1% pen/strep, 
and 5ug/mL insulin (Sigma I9278). Neurospheres: stem cell media with 10ug/mL FGF 
(R&D Systems 233-FB-025), 20ug/mL EGF (Peprotech AF-100-15) and heparin (from Dr. 
Raymund Yong, May 2015). All cells were cultured in a 37°C incubator with humidity and 
5% CO2. Cell lines were obtained from ATCC (which authenticate cell lines using several 
methods including DNA fingerprinting) in 2006, with the exception of MEFs, MCCL-278, 
and MCCL-357 which were produced in our lab from mice (2012-2016). Cell lines were 
clear of mycoplasma as determined by the Lonza kit (LT07-418) within 6 months of their 
use. Cell lines were further authenticated in 2015 by LabCorp using a short tandem repeat 
method.
Mouse Embryonic Fibroblasts
Embryos were harvested 14 days after conception from Pten flox/flox mice from Jackson 
Labs. MEFs were treated with adenovirus diluted in growth media supplemented with 
polybrene with or without cre recombinase and studied passages 2–5 post infection. Please 
see supplement for additional details.
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1500 cells per well (mouse cells) or 3000 cells per well (human cells) were plated in 96 well 
plates (Corning 720089). Growth rates were determined using the phase-confluency 
readings on an IncuCyte ZOOM (Essen Biosciences) on live cells over time.
Metabolite labeling
For glutamine flux, media without added glutamine (Corning 17-207-CV) was 
supplemented with 13C glutamine (fully labeled) or 15N glutamine (amide labeled) 
(Cambridge Isotope Labs). For glucose flux, media without added glucose (Corning 17-207-
CV) was supplemented with 13C glucose (fully labeled) (Cambridge Isotope Labs). Cells 
were plated in 10cm dishes and grown in normal media. 1 hour prior to metabolite 
extraction, media was aspirated and replaced with heavy isotope-labeled media.
Metabolic extraction
Metabolites were extracted in methanol. Please see supplement for details.
Targeted Mass Spectrometry
Mass Spec was performed by the core facility at Beth Israel Deaconess Medical Center. 
Please see supplement for details.
Cell cycle Analysis
Instructions for the FlowCellect™ Bivariate Cell Cycle Kit (Millipore FCCH025102) were 
followed. Fluorescence was measured on a Guava® flow cytometer. BrdU was pulsed for 
18hrs.
Cell death
Instructions for the FlowCellect™ Annexin Red Kit (Millipore FCCH100108) were 
followed. Fluorescence was measured on a Guava® flow cytometer.
Seahorse Analysis
A Seahorse XF (Agilent) was used to determine the oxygen consumption and extracellular 
acidification rates. Cells were plated in the Seahorse cartridge and pH-adjusted media was 
added. Oligomycin, FCCP, and rotenone (Seahorse XF kit, Agilent) were injected into 
cartridge wells. Controls for calibration and establishing baseline were used.
Drug response assays
Cells were plated in 96-well plates at a density of 1500 or 3000 cells per well. Leflunomide 
(Sigma PHR1378-1G), A771726 (Sigma SML0936), mercaptopurine (Sigma 852678), 
brequinar (Sigma SML0113), 5-fluorouracil (Millipore 343922), RAD001 and 
GDC0491(obtained from Stand Up to Cancer PI3K Dream Team pharmacy), and CB-839 
(MedChemexpress HY-12248) were dissolved in DMSO. Sensitivity was determined by a 
dose-response titration for each cell line, with an equivalent amount of DMSO in each well: 
300μL media with drug was added to one column of wells, and 150μL media with equivalent 
DMSO was added to remaining wells. Serial dilutions of 150μL resulted in a gradient with 
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half the drug concentration as the previous column while maintaining the same amount of 
DMSO. GI50 values were calculated by linear interpolation: the maximum growth 
confluence for a cell line prior to growth plateau was divided by 2 to obtain the 50% 
confluence value. A linear regression curve was calculated using drug concentrations as x-
values and confluence as y-values for points surrounding the 50% value. Linear interpolation 
using the regression line yielded the GI50 concentration. For cell death assays, DRAQ7TM 
(Cell Signaling 7406S) was added to the media at a 1:200 dilution and red fluorescence was 
measured in addition to phase in live-cell imaging to measure accumulation of dead cells. 
An IncuCyte ZOOM was used.
Gamma-H2AX measurement
Instructions for the FlowCellect™ Cell Cycle Checkpoint H2A.X DNA Damage Kit 
(Millipore FCCH12542) were followed. Briefly, cells were fixed and permeabilized, 
followed by staining with an anti-phospho-H2A.X antibody and propidium iodide. For co-
staining with RPA, an additional step was performed during which cells were incubated with 
an RPA antibody (Abcam ab79398) for 1 hour and secondary antibody for 1 hour. 
(Propidium iodide was not used in this setting.) Fluorescence was measured on a Guava® 
flow cytometer.
EdU detection
Instructions for the EdU cell proliferation Kit (Millipore 17-10525) were followed. Cells 
were fixed and permeabilized following a 45min EdU pulse and a click chemistry reaction 
was used to add a fluorescent tag. Fluorescence was measured on a Guava® flow cytometer 
or by immunofluorescence.
Immunofluorescence
Cells were plated on cover slips in media. For detecting replication forks: following a 45min 
EdU pulse, cover slip-attached cells were fixed and permeabilized, and detected after azide 
conjugation to EdU. For detecting gamma-H2AX or pTOPBP1: cells were incubated with 
primary antibody (Upstate Cell Signaling and Bethyl A300-111A-M, respectively) overnight 
at 4°C and with secondary antibody for 2 hours at room temperature. Images were taken 
using a Zeiss LSM880 Airyscan confocal microscope at 63X, and foci number and 
colocalization was quantified with Image J.
pTOPBP1 measurement
Cells were fixed and permeabilized, followed by incubation with primary antibody (Abgent 
AP3774a) for 2 hours at room temperature and secondary antibody for 2 hours at room 
temperature. Fluorescence was measured on a Guava® flow cytometer.
Karyotyping
Chromosomal analysis was performed on cultured cells treated with colcemid by Dr. Murty 
Vundavalli at Columbia University; please see supplement for details.
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Orotate (Sigma O2750) was dissolved in DMSO. Cells were plated at fixed concentration 
leflunomide with increasing concentrations of orotate, keeping DMSO constant in all wells.
Uridine Rescue
Uridine (Sigma U 3750) was dissolved in media. Cells were plated at fixed concentration 
leflunomide with increasing concentrations of orotate, keeping DMSO constant in all wells.
RNA interference
siRNA for DHODH was purchased from Qiagen. Cells were transfected using lipofectamine 
(Invitrogen 11668-019) and knockdown was confirmed at 48 hours. Scrambled siRNA was 
used as a control.
Transfection
Plasmids were electroporated into cells (1 million) using an Amaxa Nucleofector™ 2b 
(Lonza) and Cell Line Nucleofector® Kit V (Lonza VCA-1003). An mcherry plasmid was 
co-transfected to determine transfection efficiency and to gate transfected cells for flow 
cytometry experiments.
Xenografts
6-week old female nu/nu mice were engrafted orthotopically with either 5 million SUM149, 
5 million MDAMB 468-luciferase, 1 million MCCL-357, or .75million MCCL-278 cells. 
Mice were treated by oral gavage with 100mg/kg leflunomide or vehicle (1% 
carboxymethylcelluose in water). Animal experiments were approved by an Institutional 
Animal Care and Use Committee.
Neurosphere sensitivity assay
Neurospheres were disrupted by manual pipetting until single cell suspension was achieved, 
and 10,000cells/well were plated in low-attachment 6-well plates (Fisher 3471). After 5 
days, neurospheres were counted; sphere-forming ability is an indicator of tumorigenicity. 
Dense clusters >.05mm in diameter were counted as true tumor spheres. Spheres were 
measured on ImageJ and quantified.
Statistical Analysis
ANOVA or student’s t-tests were used to test means between groups. Correction for multiple 
comparisons was added where needed. Analysis was done using GraphPad Prism 6 or 
Microsoft Excel.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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We have found a prospective targeted therapy for PTEN deficient tumors, with efficacy in 
vitro and in vivo in tumors derived from different tissues. This is based upon changes in 
glutamine metabolism, DNA replication, and DNA damage response which are 
consequences of inactivation of PTEN.
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(A) Growth of Pten WT and KO MEFs (one-way ANOVA, *p<.0001, n=3). (B) MEFs 
labeled with EdU. Representative confocal microscopy images. (C) Quantification of Fig.1B 
(Student’s t-test, *p<.05, n=6). (D) MEFs labeled with EdU; flow cytometry determined the 
mean fluorescence intensity among cells positively stained (Student’s t-test, *p<.01, n=3). 
(E) Pten WT and KO MEFs in media containing full glutamine (6mM) or no added 
glutamine (one-way ANOVA, *p<.0001, n=3). (F) MEFs treated with 12.5nM CB-839 or 
control (one-way ANOVA, *p<.0001, n=3). (G) Relative metabolite concentrations of DNA 
nucleotide precursors (dGMP was unable to be measured so dGTP was used) (Student’s t-
test, *p<.05, n=3). (H) Relative metabolite levels of glutamine-labeled de novo pyrimidine 
synthesis intermediates (Student’s t-test, *p<.05, n=3). Data were also analyzed with 
IMPaLA: 13C glutamine-derived pyrimidine metabolism enrichment in PTEN−/− MEFs q-
value = 3.92×10−09. (I) Schematic of the de novo pyrimidine synthesis pathway. Not every 
intermediate was measured in our mass spec panel. Data shown as means + SD.
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(A) Pten WT and KO cells treated with dose titrations of leflunomide, A771726, or 
brequinar to determine GI50s (Student’s t-test, *<.05, n=3). (B, C) Cells treated with dose 
titrations of leflunomide to determine GI50s (Student’s t-test, *p-values on figures, n=3). (D, 
E) Cells treated with 100μM leflunomide and DRAQ7 to monitor accumulation of cell 
death, in intervals of 6 hours (one-way ANOVA, *p-values on the figures). (F) Human breast 
cancer cell line growth rates. (G) Immunoblots of pAKT in nuclear fractions of Pten−/− and 
Pik3ca mutant MEFs. (H) Cells treated with 50μM leflunomide in combination with 0 or 
640μM orotate. Confluence of cells after 5 days of treatment was measured (Student’s t-test, 
*p<.05, n=3). (I) Cells treated with 50μM leflunomide in combination with 0, 31.25, 62.5 or 
125μM orotate. Confluence of cells after 5 days was measured (Student’s t-test, *p<.05, 
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n=3). (J) Cells treated with 100μM leflunomide in combination with 0 or 3.125mM uridine. 
Confluence of cells after 5 days of treatment was measured (Student’s t-test, *p<.05, n=3). 
(K) Cells treated with 100μM leflunomide in combination with 0, 3.125, or 6.25mM uridine. 
Confluence of cells after 5 days was measured (Student’s t-test, *p<.05, n=3). Data shown as 
means + SD.
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(A) Dispersed (single cell suspension) glioblastomas were treated with DMSO or 50, 100, or 
200μM leflunomide for 5 days. The number of re-formed 3-dimensional tumor spheres was 
quantified and normalized to untreated samples. (Student’s t-test, *p<.05, n=3). (B) 
SUM149 xenografts. Mice were treated with 100mg/kg leflunomide or vehicle on days 
indicated with arrows (one-way ANOVA with multiple t-tests, corrected for multiple 
comparisons, *p<.01 for ANOVA and t-tests, n=6). (C) MDA-MB 468 xenografts 
expressing luciferase, normalized to control. Treatment was started on day 7, with 100mg/kg 
leflunomide or vehicle for four consecutive days each week (one-way ANOVA with multiple 
t-tests, corrected for multiple comparisons, *p<.05 for ANOVA and t-tests, n=5). Right 
panel: luminescence of treated and control mice after 2 weeks of treatment. Data shown as 
means + SD for (A) and + SEM for (B)-(C).
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(A) Cells were labeled with a gamma-H2AX antibody. Flow cytometry determined the mean 
fluorescence intensity (MFI) (Student’s t-test, *p<.05, n=3). (B-C) Cells treated with 100μM 
leflunomide or A771726 were labeled with a gamma-H2AX antibody. Flow cytometry 
determined the mean fluorescence intensity (MFI) (Student’s t-test, *p-values on figures, 
n=3). (D) MEFs treated with 150μM A771726 for 24h, labeled with EdU and gamma-
H2AX. Left: representative confocal microscopy images. Right: quantified EdU and gamma-
H2AX colocalized foci (Student’s t-test, *p<.05, n=3). (E) Cells treated with 100μM 
leflunomide with or without uridine and labeled with a gamma-H2AX antibody. Flow 
cytometry determined the mean fluorescence intensity (MFI) (Student’s t-test, *p-values on 
figures, n=3). (F) MEFs treated with 100μM leflunomide or control for 48h and labeled with 
EdU. Left: representative confocal microscopy images. Right: quantification of the number 
of foci per cell (Student’s t-test, p>.05, n=6). (G) Cells were labeled with a pTOPBP1 S1159 
antibody. Flow cytometry determined the mean fluorescence intensity (MFI) (Student’s t-
test, *p<.05, n=3). (H) Cells treated with 150μM A771726 for times indicated and labeled 
with antibodies to RPA and gamma-H2AX. Flow cytometry determined the percentage of 
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the cell population positively-stained for RPA alone or both RPA and gamma-H2AX 
(Student’s t-test, *p<.05, n=4). (I) pCHK1 immunoblot after 150μM A771726 treatment for 
times indicated. (J-K) Quantified chromosomal breaks and multiradial formations per 
haploid genome (Student’s t-test, *p-values on figure, cells scored/replicate>100). (L) PTEN 
mutant cells were transfected with either WT TOPBP1 and CHK1, or mutants incapable of 
being phosphorylated by AKT, and labeled with a gamma-H2AX antibody after 100μM 
leflunomide treatment. Flow cytometry determined the mean fluorescence intensity (MFI) 
(Student’s t-test, *p<.05, n=3). (M) PTEN mutant cells were transfected with either WT 
TOPBP1 and CHK1, or mutants incapable of being phosphorylated by AKT, and DRAQ7 
was used to monitor accumulation of cell death in intervals of 6 hours (one-way ANOVA, 
*p<.05, n=3). Data shown as means + SD.
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